Dyne Therapeutics, Inc.
DYN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $2 | $0 | $0 |
| Gross Profit | -$2 | -$2 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $281 | $211 | $143 | $121 |
| G&A Expenses | $62 | $31 | $28 | $29 |
| SG&A Expenses | $62 | $31 | $28 | $29 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$2 | $0 | $0 |
| Operating Expenses | $342 | $240 | $171 | $150 |
| Operating Income | -$344 | -$242 | -$171 | -$150 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $26 | $6 | $3 | $1 |
| Pre-Tax Income | -$317 | -$236 | -$168 | -$149 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$317 | -$236 | -$168 | -$149 |
| % Margin | – | – | – | – |
| EPS | -3.37 | -3.95 | -3.23 | -2.93 |
| % Growth | 14.7% | -22.3% | -10.2% | – |
| EPS Diluted | -3.37 | -3.95 | -3.23 | -2.93 |
| Weighted Avg Shares Out | 94 | 60 | 52 | 51 |
| Weighted Avg Shares Out Dil | 94 | 60 | 52 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $27 | $8 | $3 | $1 |
| Interest Expense | $0 | $0 | $3 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $1 |
| EBITDA | -$315 | -$233 | -$169 | -$149 |
| % Margin | – | – | – | – |